Advertisements


Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

Category: topSource: foxnewsApr 16th, 2018

Shire sells cancer drugs to Servier as Takeda circles

Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceu.....»»

Category: videoSource: reutersApr 16th, 2018

Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

Category: topSource: foxnewsApr 16th, 2018

Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles

LONDON (Reuters) - Shire , the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical , is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion......»»

Category: topSource: reutersApr 16th, 2018

Shire Sells Oncology Unit Ahead of Takeda"s Potential Offer

Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. T.....»»

Category: smallbizSource: nytApr 17th, 2018

Japan"s Takeda clinches $62 billion Shire deal as pharma M&A rolls on

LONDON/TOKYO (Reuters) - Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry......»»

Category: topSource: reutersMay 8th, 2018

Japan"s Takeda sweetens $62 billion Shire offer

TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals......»»

Category: topSource: reutersApr 20th, 2018

Shire to Sell Oncology Unit as Takeda Mulls Takeover

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Category: smallbizSource: wsjApr 16th, 2018

Shire to Sell Oncology Unit for $2.4 Billion as Takeda Mulls Takeover

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Category: smallbizSource: wsjApr 16th, 2018

Takeda receives FTC clearance for Shire acquisition

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018

Japan"s Takeda gains U.S. approval for $62 billion Shire buy

Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker......»»

Category: topSource: reutersJul 10th, 2018

Takeda gets key U.S. regulatory approval to buy Shire

Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc......»»

Category: topSource: reutersJul 10th, 2018

AstraZeneca"s Two New Cancer Drugs Get Approval in Japan

AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication a.....»»

Category: worldSource: nytJul 3rd, 2018

Takeda shareholders reject proposal from anti-Shire group, Reuters reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2018

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor

TOKYO (.....»»

Category: topSource: reutersJun 28th, 2018

Takeda shareholder group proposal fails to pass at AGM

TOKYO (Reuters) - A group of Takeda Pharmaceutical Co Ltd shareholders trying to build support to block the $62 billion acquisition of London-listed Shire Plc failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday......»»

Category: topSource: reutersJun 28th, 2018

Takeda chief looks to allay Shire bid concerns, FT reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 27th, 2018

Latecomer Sanofi looks to catch next wave of cancer therapies

PARIS (Reuters) - Sanofi missed the boat on immune system-boosting cancer drugs. Now it's trying to catch up......»»

Category: topSource: reutersJun 20th, 2018

Sanofi believes it can make comeback in cancer drugs, Reuters reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Takeda and Shire Have a $60 Billion Drug Problem

Takeda and Shire Have a $60 Billion Drug Problem.....»»

Category: topSource: washpostJun 12th, 2018

Takeda shareholder group aims to block $62B Shire deal

A group of Takeda Pharmaceutical shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire at an extraordinary general meeting, a leading member of the group told Reuters on Monday......»»

Category: topSource: moneycentralJun 11th, 2018